Literature DB >> 8109319

Pathways of Ras function: connections to the actin cytoskeleton.

G C Prendergast1, J B Gibbs.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8109319     DOI： 10.1016/s0065-230x(08)60314-0

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  21 in total

1.  Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells.

Authors:  S M Oldham; G J Clark; L M Gangarosa; R J Coffey; C J Der
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  TC21 causes transformation by Raf-independent signaling pathways.

Authors:  S M Graham; A B Vojtek; S Y Huff; A D Cox; G J Clark; J A Cooper; C J Der
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

3.  Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation.

Authors:  R Khosravi-Far; P A Solski; G J Clark; M S Kinch; C J Der
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

4.  Dynamics of active lamellae in cultured epithelial cells: effects of expression of exogenous N-ras oncogene.

Authors:  N A Gloushankova; M F Krendel; V A Sirotkin; E M Bonder; H H Feder; J M Vasiliev; I M Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

5.  Shk1, a homolog of the Saccharomyces cerevisiae Ste20 and mammalian p65PAK protein kinases, is a component of a Ras/Cdc42 signaling module in the fission yeast Schizosaccharomyces pombe.

Authors:  S Marcus; A Polverino; E Chang; D Robbins; M H Cobb; M H Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

Review 6.  Aberrant function of the Ras signal transduction pathway in human breast cancer.

Authors:  G J Clark; C J Der
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

7.  Changes in tyrosine-phosphorylated p190 and its association with p120 type I and p100 type II rasGAPs during myelomonocytic differentiation of human leukemic cells.

Authors:  J C Cheng; A R Frackelton; E L Bearer; P S Kumar; B Kannan; A Santos-Moore; A Rifai; J Settleman; J W Clark
Journal:  Cell Growth Differ       Date:  1995-02

Review 8.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.

Authors:  G C Prendergast; J P Davide; S J deSolms; E A Giuliani; S L Graham; J B Gibbs; A Oliff; N E Kohl
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 10.  Farnesyltransferase inhibitors and anti-Ras therapy.

Authors:  J B Gibbs; N E Kohl; K S Koblan; C A Omer; L Sepp-Lorenzino; N Rosen; N J Anthony; M W Conner; S J deSolms; T M Williams; S L Graham; G D Hartman; A Oliff
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.